GB-4362 + enfortumab vedotin (EV) + Pembrolizumab
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Urothelial Cancer
Conditions
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Trial Timeline
Mar 1, 2026 → Dec 1, 2027
NCT ID
NCT07484022About GB-4362 + enfortumab vedotin (EV) + Pembrolizumab
GB-4362 + enfortumab vedotin (EV) + Pembrolizumab is a phase 1 stage product being developed by Generate Biomedicines for Advanced Urothelial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07484022. Target conditions include Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Urothelial Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07484022 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Urothelial Cancer